Innovation Pharmaceuticals Inc (IPIX)

[KMBJN]

Here is the link to the Prurisol patent again:

http://www.google.com/patents/WO2013103601A1?cl=en

"the present invention relates to novel esters of abacavir" so it seems like it would cover other abacavir esters (like studied by the Bulgarian group), but not generic abacavir sulfate or Ziagen (now off patent).

The patent only says that Prurisol and related compounds directly or indirectly produce anti-inflammatory compounds, and will be used to treat inflammatory skin diseases. Perhaps the PRINS lncRNA reduction is merely a side effect of reduced inflammatory / cellular stress response due to some other mechanism of action of Prurisol that is not related to its antiviral activity? The antiviral activity is by conversion to abacavir, then intracellularly to the active metabolite, carbovir triphosphate.

http://www.rxlist.com/ziagen-drug/clinical-pharmacology.htm

Prurisol is described as acting according to the "principles of immune modulation and PRINS reduction."

Interestingly, Prurisol is 25% orally bioavailable, whereas Ziagen is 83%.

http://cellceutix.com/cellceutix-signs-agreement-for-clinical-trial-in-europe-on-new-psoriasis-drug/